NEW YORK (GenomeWeb) – The US Food and Drug Administration on Friday approved the first lung cancer immunotherapy drug for a molecularly defined subset of patients.
Merck's anti-PD-1 drug Keytruda (pembrolizumab) is indicated for advanced non-small cell lung cancer patients who have progressed despite receiving platinum-containing chemotherapy or agents targeting EGFR or ALK tumor mutations, and whose tumors are positive for PD-L1 expression.
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try Premium Access now.
You may already have institutional access!
Check if I qualify.
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
